DNLI - Denali Therapeutics Inc Latest SEC Filings
This page provides a detailed financial overview and snapshot of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It also lists the company's SEC filings and provides a general market overview for the biotechnology sector.
Denali Therapeutics stock stays focused on pipeline progress.
Denali Therapeutics' stock performance is closely tied to the progress of its neuroscience and lysosomal disease pipeline, with investors monitoring development milestones. The company's focus on transport vehicle technology to cross the blood-brain barrier is central to its drug development strategy. Despite being a development-stage biotech, its Nasdaq listing keeps it within the broader biotechnology sentiment, making pipeline readouts crucial for its future outlook.
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK
The Amyotrophic Lateral Sclerosis (ALS) market is projected to expand significantly by 2034, driven by an increasing disease prevalence, advancements in drug development, and growing regulatory support. The market experienced an estimated size of USD 850 million in the United States alone in 2025, with a robust pipeline of therapies from companies like Helixmith, Sanofi, and GSK. Despite challenges like complex disease biology and high clinical trial failure rates, significant investments and strategic collaborations are fostering the development of novel treatments for this neurodegenerative disease.
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK
The Amyotrophic Lateral Sclerosis (ALS) market is projected to grow significantly by 2034, driven by an expanding drug pipeline and increased investment. DelveInsight's report highlights key companies like Helixmith, Sanofi, and GSK, and details recent advancements including FDA designations and clinical trial progress for various novel therapies. The US currently holds the largest market share in the 7MM (seven major markets).
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article focuses on the enterprise value to EBIT forward metric for Denali Therapeutics Inc. (NASDAQ: DNLI). It presents financial data related to this specific valuation ratio for the biotechnology company. The content appears to be a stub or a section from a financial data platform like TradingView, showing the absence of detailed analysis or narrative.
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article provides a financial statistic for Denali Therapeutics Inc. (NASDAQ: DNLI). Specifically, it presents the "Price to sales forward" metric for the company. The content appears to be a snapshot from a financial data platform, likely TradingView, showing overview information for DNLI.
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh
This page displays financial information for Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (BMFBOVESPA:D2NL34), specifically its price-to-sales forward ratio. The content appears to be a financial data presentation page from TradingView, offering an overview of the security's financials.
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This page provides financial data, specifically the "Price to earnings forward" for Denali Therapeutics Inc. (NASDAQ: DNLI). It indicates that the company's stock is listed on the Nasdaq Stock Market and that the market was closed at the time of the data query, with no trades having occurred. The content also lists various financial tools and data sources used by TradingView.
Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN)
This article provides an overview of Denali Therapeutics Inc. (DUS:4DN) financials, analyst estimates, and historical stock performance. It includes details on revenue, earnings per share, net income, key dates like the next earnings report on July 30, 2026, and a stock forecast with max and min estimates of 36.18 EUR and 19.81 EUR respectively. The company does not pay dividends and has 503 employees as of June 28, 2026.
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article provides the enterprise value to EBITDA forward for Denali Therapeutics Inc. (NASDAQ: DNLI). It appears to be a financial data snippet from TradingView, concentrating solely on this specific financial metric for the biotechnology company. The content confirms that no trades were made when the market was closed.
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI)
This article provides an overview of Denali Therapeutics Inc. (NASDAQ: DNLI) stock, including current prices, historical performance, analyst forecasts, and financial data. It highlights the company's recent stock growth, market capitalization, and upcoming earnings report date, along with past earnings and revenue figures. The piece also addresses frequently asked questions about investing in DNLI stock, its volatility, and where to track its financials.
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh
This article provides financial information for Denali Therapeutics Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (D2NL34 B3) on TradingView, focusing on its Enterprise Value to EBITDA forward ratio. It seems to be a financial data page rather than a traditional news article, presenting current market status and various data points related to the company's financial performance. The page indicates that the market is currently closed with no trades.
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh
This page provides financial information for Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (D2NL34) on the BMFBOVESPA exchange, specifically focusing on its Price to Earnings Forward metric. It indicates that the market was closed with no trades recorded at the time of viewing. The content also lists various features and resources provided by TradingView.
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing
This article analyzes Denali Therapeutics Inc. (DNLI) using AI models to determine its impact on rotational strategy timing. It highlights strong sentiment across all horizons supporting an overweight bias and identifies no resistance levels above the current price, suggesting significant upside potential. Three distinct trading strategies—position trading, momentum breakout, and risk hedging—are presented, along with multi-timeframe signal analysis to guide investors.
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing
This article analyzes Denali Therapeutics Inc. (DNLI) using AI models to determine its effect on rotational strategy timing. Key findings indicate strong sentiment across all time horizons, supporting an overweight bias, with no resistance levels identified above the current price. It presents three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, alongside a multi-timeframe signal analysis for near-term, mid-term, and long-term perspectives.
Denali Therapeutics options trading jumps to 2,291 contracts
Denali Therapeutics Inc. saw a significant increase in options trading, with 2,291 contracts traded by Thursday afternoon. Call volume heavily outweighed put volume, and the July 17, 2026 $30 call option was particularly active. Coinciding with this, Denali Therapeutics shares experienced a slight rise, and its three-month volatility and skew also increased.
Denali Therapeutics stock hits 52-week high at 25.74 USD
Denali Therapeutics stock reached a new 52-week high of $25.74, reflecting a significant 72% increase over the past year and strong investor confidence. While the stock appears overvalued according to InvestingPro analysis, the company continues to make progress in neurodegenerative disease treatments, evidenced by a recent Priority Review Voucher sale for $195 million. Despite a setback in a Parkinson's trial, analyst ratings remain positive, highlighting ongoing therapeutic developments and market engagement.
DNLI Forecast — Price Target — Prediction for 2027
This article provides an overview of Denali Therapeutics Inc. (DNLI) stock, including its current price, market capitalization, and analyst forecasts for 2027. Analysts predict a maximum price of $42.00 USD and a minimum of $23.00 USD for DNLI. The company's financial performance, upcoming earnings date, and employee count are also detailed.
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million
Denali Therapeutics (DNLI) saw an 8.2% increase in its stock price after selling its FDA Rare Pediatric Disease Priority Review Voucher for $195 million. This non-dilutive funding provides financial flexibility to advance its lysosomal storage and neurodegenerative disease programs without issuing new equity. The move strengthens the company's balance sheet and alleviates pressure for future equity raises, shifting the investment focus from funding capacity to the scientific delivery of its pipeline.
Stifel reiterates Buy rating on Denali Therapeutics stock at $41
Stifel reiterated a Buy rating and $41 price target on Denali Therapeutics (NASDAQ:DNLI) after meeting with company executives. The company's stock has surged 68% over the past year, and management discussed the successful launch of Avlayah and upcoming data for DNL126 and BIIB080. Other pipeline developments and recent financial transactions were also highlighted, despite a setback in a Parkinson's trial.
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million
Denali Therapeutics (DNLI) is up 8.2% after selling its FDA Rare Pediatric Disease Priority Review Voucher for $195 million in cash. This sale provides non-dilutive funding, giving Denali financial flexibility to advance its lysosomal storage and neurodegenerative disease programs without issuing new equity. The move strengthens the company's balance sheet and helps manage funding risks, although clinical and commercialization uncertainties remain.
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod
Denali Therapeutics has monetized its Rare Pediatric Disease Voucher for $195 million following the FDA approval of its drug Avlayah. This financial transaction comes shortly after related news regarding Denali's other pipeline developments, including the discontinuation of a Parkinson's drug in collaboration with Biogen. The deal highlights Denali's strategic financial management post-approval.
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod
Denali Therapeutics has monetized a Rare Pediatric Disease Voucher for $195 million following the FDA approval of its drug, Avlayah. This deal comes after Avlayah's recent approval for Hunter Syndrome, a rare genetic disorder. The company had previously been involved in other developments, including the discontinuation of a Parkinson's drug.
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million, following the FDA's accelerated approval of AVLAYAH for Hunter syndrome. The proceeds will be used to advance Denali's extensive clinical pipeline, which includes programs for lysosomal storage disorders and neurodegenerative diseases. This sale aims to strengthen the company's financial flexibility and accelerate the development of its TransportVehicle™-enabled therapeutics designed to cross the blood-brain barrier.
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for Denali Therapeutics Inc (DNLI). It states that Denali Therapeutics has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The page also presents current stock price information and market capitalization for DNLI.
Denali Therapeutics to sell priority review voucher for $195m
Denali Therapeutics Inc. announced its agreement to sell a Rare Pediatric Disease Priority Review Voucher for $195 million. This voucher was awarded after the FDA approved AVLAYAH for Hunter syndrome. The proceeds will fund Denali's expansive clinical pipeline, which includes treatments for various neurodegenerative and lysosomal storage disorders.
Denali to sell priority review voucher for $195M (DNLI:NASDAQ)
Denali Therapeutics (DNLI) will sell its rare pediatric disease priority review voucher for $195 million, leading to a spike in pre-market shares. This voucher was obtained following a recent FDA approval for one of its therapies.
Denali Therapeutics to Sell FDA Priority Review Voucher for $195 Million
Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $195 million in cash. This voucher was obtained after the FDA approval of AVLAYAH for Hunter syndrome in March 2026. The company expects this transaction to monetize a non-core asset and increase its financial flexibility.
Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M
Denali Therapeutics Inc. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash. This voucher was awarded following the FDA's accelerated approval of AVLAYAH for Hunter syndrome in March 2026. The proceeds are intended to support Denali's TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.
Denali’s rare disease voucher sale brings in $195 million
Denali Therapeutics (Nasdaq: DNLI) announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million. This voucher was granted following the FDA's accelerated approval of AVLAYAH for Hunter syndrome in March 2026. Denali plans to use the proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.
Denali Therapeutics stock hits 52-week high at 23.78 USD By Investing.com
Denali Therapeutics (DNLI) stock recently hit a 52-week high of $23.78, currently trading at $23.80, reflecting a strong upward trend with significant yearly returns. Despite InvestingPro analysis suggesting overvaluation and anticipated unprofitability this year, investor confidence remains high, bolstered by a $200 million royalty agreement and FDA approval for its drug Avlayah. However, the company also faced a setback with the failure of its Parkinson's treatment in a Phase 2b clinical trial.
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01
This article provides a transcript of Denali Therapeutics Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation featured CEO Ryan Watts and another individual named Alex. The full article content is reserved for subscribers.
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch By Investing.com
UBS has reiterated a Buy rating and a $25.00 price target for Denali Therapeutics (NASDAQ:DNLI) following the positive early launch indicators for its drug, Avlayah, for Hunter syndrome. The drug, priced at a significant premium to its competitor, is expected to follow an S-shaped launch curve with accelerated growth in 2027 and 2028, supported by global expansion efforts and upcoming study readouts. Despite a setback in its Parkinson's treatment, recent FDA approval for Avlayah and financial endorsements highlight its significant potential.
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch By Investing.com
UBS reiterated a Buy rating and $25.00 price target for Denali Therapeutics Inc. (NASDAQ:DNLI) following positive early indicators for the Avlayah launch, a new drug for Hunter syndrome. The drug has seen rapid commercial deployment and positive payer reception, despite being priced at a premium. The company expects an "S-shaped" growth curve, with significant acceleration anticipated in 2027 and 2028, supported by upcoming global expansion and confirmatory study readouts.
Denali Therapeutics Inc (DNLI) Earnings Forecast: Future EPS & Revenue Growth Estimates
Denali Therapeutics Inc (DNLI) has an earnings forecast score of 8.84, ranking 49th in the Biotechnology & Medical Research industry. Analysts provide an average target price of $32.00, with a consensus leaning towards a "Buy" rating. The company's expected revenue for the next quarter is $1.15 million, and its EPS for the previous quarter was -$0.73, with an expectation of -$0.67 for the next quarter.
(DNLI) and the Role of Price-Sensitive Allocations
This article provides an analysis of Denali Therapeutics Inc. (DNLI) based on AI-generated signals, indicating a strong overweight bias across all trading horizons. It highlights an exceptional risk-reward setup targeting a 12.8% gain and outlines three distinct institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis, providing support and resistance levels for near-term, mid-term, and long-term trading.
10 Best AI Driven Biotech Stocks to Invest In
This article highlights Denali Therapeutics Inc. (NASDAQ: DNLI) as one of the top AI-driven biotech stocks. It discusses Denali's recent clinical trial results for a Parkinson's drug, which missed primary endpoints, leading to a partnership halt with Biogen but reaffirming the drug's biological targets. Despite a lowered price target by Morgan Stanley, the firm maintains an Overweight rating, emphasizing the company's other pipeline assets and platform validation.
10 Best AI Driven Biotech Stocks to Invest In
This article discusses Denali Therapeutics Inc. (NASDAQ: DNLI) as one of the top AI-driven biotech stocks. It details the company's recent Phase 2b LUMA trial results for Parkinson's disease, which missed primary endpoints but showed biological target engagement. Despite a lowered price target from Morgan Stanley, Denali plans further trials for a specific genetic mutation, and the firm still sees significant upside potential.
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
Denali Therapeutics (DNLI) is highlighted as a top AI-driven biotech stock despite a recent setback. The company's joint work with Biogen on BIIB122 for Parkinson's disease was halted after Phase 2b trial results showed no improvement over placebo. However, lab tests confirmed the drug hit its biological targets, and Denali plans to continue independent trials for a specific genetic mutation, with Morgan Stanley maintaining an "Overweight" rating and a price target suggesting significant upside.
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment
The failure of Biogen and Denali’s LRRK2 inhibitor (BIIB122) in a Phase IIb study for Parkinson's disease, which enrolled patients regardless of LRRK2 genetic variant status, is redirecting research focus. This setback suggests that future trials for LRRK2 inhibitors may need to prioritize genetically enriched patient populations, rather than broadly targeting all Parkinson's patients. Denali is now independently testing BIIB122 in a smaller trial specifically limited to confirmed variant carriers.
Denali Therapeutics (DNLI) director receives new RSU and stock option grants
Denali Therapeutics (DNLI) director Timothy Van Hauwermeiren received new equity awards comprising 6,408 Restricted Stock Units (RSUs) and options to purchase 19,226 shares. These awards are part of his compensation, not open-market transactions, and will vest 100% on the earlier of one year from the grant date or the day before Denali's next annual meeting. Following these grants, he holds 17,040 unvested RSUs.
Director at Denali Therapeutics (NASDAQ: DNLI) receives RSUs and options
Denali Therapeutics director Nancy Thornberry was granted 6,408 Restricted Stock Units (RSUs) and a stock option for 19,226 shares with an exercise price of $19.66. Both equity awards will vest upon the earlier of one year from the grant date or the day before the next annual stockholder meeting. Following these transactions, Thornberry directly holds 31,125 shares of common stock, including the unvested RSUs.
Denali Therapeutics (NASDAQ: DNLI) details Baker RSU and stock option grants
Denali Therapeutics (NASDAQ: DNLI) director Julian C. Baker was granted 6,408 restricted stock units (RSUs) and 19,226 non-qualified stock options, with a strike price of $19.66, vesting in 2027. These equity awards are compensation for his board service and are indirectly held by Baker Brothers funds. The transaction is considered routine compensation, not open-market trading, and significantly increases the Baker complex's potential future exposure to Denali.
Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay
Denali Therapeutics Inc. announced the results of its annual stockholder meeting held on June 3, 2026. Shareholders approved the election of three Class III directors, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and approved the compensation of named executive officers on an advisory basis. The meeting saw strong participation, with 86.96% of outstanding shares represented.
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy?
Denali Therapeutics (DNLI) and Biogen recently announced that their Phase 2b LUMA study for BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the drug for idiopathic Parkinson's disease. This setback impacts Denali's investment narrative by removing a broad Parkinson's catalyst and increasing reliance on its other pipeline assets and AVLAYAH uptake. Despite the clinical failure, the trial provided valuable scientific insights into LRRK2 biology.
DNLI Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for Denali Therapeutics Inc. (DNLI), including past quarterly results and future forecasts. It details analyst estimates for upcoming quarters, the impact of estimate revisions on stock price, and historical stock price reactions around earnings release dates. The analysis also covers key highlights from a previous earnings report and offers insights into investor expectations.
A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline
Denali Therapeutics (DNLI) is under scrutiny after a Phase 2b trial failure, causing investors to re-evaluate its pipeline of neurodegenerative and lysosomal disease treatments. Despite short-term buying interest following the news, the company has a loss-making profile and a significant gap to analyst targets, with its current Price-to-Book ratio of 3.6x indicating it trades below direct peers but above the broader US biotech benchmark, while a Discounted Cash Flow model suggests the stock's current price may be overly optimistic. Investors are advised to consider the underlying data and risks associated with Denali's early-stage programs and current losses.
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Therapeutics maintains a "Strong Buy" rating due to the FDA Accelerated Approval of AVLAYAH for Hunter syndrome and promising pipeline developments. The company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN, with Phase 1/2 data expected by the end of 2026. Despite a strong cash position of $1.05 billion, the company may require additional funding within 12 months, using a $400 million ATM facility for potential dilution.
Denali stock dips as Biogen-partnered Parkinson's disease study fails
The article reports that Denali Therapeutics' stock experienced a dip after its Parkinson's disease study, partnered with Biogen, failed to meet its primary endpoint. This clinical trial outcome likely raised concerns among investors regarding the drug's efficacy and future development prospects.
Denali stock dips as Biogen-partnered Parkinson's disease study fails
Denali Therapeutics' stock dipped following the failure of a Parkinson's disease study, which was being developed in partnership with Biogen. The study, involving the drug BIIB122, did not meet its primary endpoint, raising concerns about the future of the partnership and the drug's efficacy. This setback could impact Denali's pipeline and financial outlook as they reassess their strategic direction in neurodegenerative disease research.
